Retinal Biologics Market Trends

• Retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are becoming more common globally. Factors such as aging populations and higher rates of diabetes contribute to this increase.
  
• For instance, as per the International Diabetes Foundation, in 2021 approximately 537 million people were living with diabetes and the number of people with diabetes is projected to rise to 643 million and 783 million by 2030 and 2045 respectively. As the prevalence of these conditions rises, so does the demand for effective treatments to manage them.
  
• Retinal biologics, such as anti-VEGF therapies, have become a standard of care for many retinal diseases, providing targeted treatments that improve patient outcomes. Thus, with growing patient population, there is a substantial demand for effective treatment options, thereby driving the market growth.
  
• Additionally, there is a strong focus on research and development (R&D) in the field of retinal biologics as companies strive to improve existing treatments and develop new therapies. This includes efforts to create biologics with longer durations of action, reducing the frequency of treatments for patients. These R&D efforts drive innovation, lead to the introduction of new products, and increase the range of treatment options available in the market, fostering growth and competition.